Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial
This study in Japanese patients with familial adenomatous polyposis (n=104) found that aspirin (100mg per day) but not mesalazine (2g per day) was associated with a reduced risk of recurrence of colorectal polyps of ≥5mm at 8 months (OR for aspirin: 0.37; 95% CI 0.16–0.86).
Source:
The Lancet Gastroenterology and Hepatology